Blackhawk Growth Corp Acquires Trip Pharma Inc.

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.

Stella Acquires U.S. Assets of Field Trip Health

June 27, 2023

Healthcare Services

Stella (Stella MSO, Inc.) acquired the U.S. assets of Field Trip Health & Wellness Ltd., including clinics, technology, research data and leadership to expand its psychedelic and ketamine therapy offerings. The deal brings Field Trip clinics in New York and Washington, D.C. into Stella’s network and adds senior Field Trip executives to Stella’s leadership team to help integrate the assets and scale services.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

Champignon Brands Acquires AltMed Capital Corp.

April 9, 2020

Healthcare Services

Champignon Brands Inc. has entered into a definitive agreement to acquire 100% of AltMed Capital Corp., a Canadian ketamine clinic operator and psychedelic medicine IP aggregator that owns a majority stake in the Canadian Rapid Treatment Centre of Excellence (CRTCE) in Mississauga. The acquisition gives Champignon clinic SOPs, Health Canada-approved psilocybin dosing capability, existing IP and an early-stage clinical trials portfolio to accelerate its psychedelic medicine and rapid-onset treatment rollout in Canada and the United States.

Karo Pharma Acquires Trimb Healthcare from Avista Capital Partners

June 25, 2019

Pharmaceuticals

Karo Pharma AB (publ) has signed a definitive agreement to acquire Trimb Healthcare from Avista Capital Partners for SEK 3.4 billion. Trimb, a Stockholm‑based consumer healthcare company with ~90 employees and a portfolio of OTC brands, will expand Karo Pharma's geographic presence, distribution channels and product offerings in the Nordic and Northern European consumer health market.

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.